Moderna stock has surged over 600% in 2026, outperforming major AI stocks like Nvidia, Micron, and Sandisk, driven by progress in its oncology pipeline, particularly its personalized cancer vaccine candidate intismeran autogene. The stock now trades 61% above Wall Street's average price target of $122, and while the company shows promise as it transforms from a coronavirus vaccine company into a broader biotech player, the analyst recommends waiting for a pullback before buying.

Moderna's stock gained over 5% in a week, adding $4.2 billion in market value, driven by positive phase III melanoma results for its cancer therapy intismeran and inclusion in the Nasdaq-100 Index. While the company shows promise in oncology and respiratory vaccines, its 625% YTD rally has resulted in a premium valuation that leaves it vulnerable to disappointment. The stock is rated a Hold, with short-term investors advised to book profits while long-term investors may consider holding for future growth opportunities.

The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline. Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential.

Moderna (MRNA) declined 5.05% to $213.63 in the latest trading session, underperforming the S&P 500. Despite a 56.28% gain over the past month, the company faces headwinds with projected quarterly EPS of -$1.37 (down 168.63% YoY) and revenue expected at $888.78 million (down 12.52% YoY). The stock holds a Zacks Rank #3 (Hold) rating with consensus EPS estimates revised 0.35% lower in the past month.

Tempus AI (TEM) is strengthening its precision medicine presence through multiple strategic collaborations, including support for Moderna and Merck's cancer therapy commercialization and an extended data partnership with Recursion Pharmaceuticals through 2029. However, TEM's stock has underperformed the industry by 30.6% over the past year and trades at a premium valuation of 6.73X forward P/S versus the industry average of 4.90X, with the stock currently rated a Hold.

Moderna stock has surged over 500% this year, driven by investor enthusiasm about its personalized cancer vaccine candidate. The stock now trades 61% above Wall Street's average price target. While the stock may face near-term pullback after its rapid gains, the company's strong pipeline and long-term growth potential in mRNA-based therapies suggest it remains a solid long-term biotech investment, though scaling personalized vaccines presents manufacturing challenges.

Moderna (MRNA) will be added to the Nasdaq-100 Index on October 9, replacing Warner Bros. Discovery following its acquisition by Paramount. The inclusion comes after Moderna's 566% year-to-date stock surge and positive phase III results for its personalized cancer therapy developed with Merck. While the index addition could drive incremental institutional demand through index-tracking funds managing over $800 billion in assets, it does not change the company's underlying fundamentals.

The article provides an in-depth analysis of the Invesco S&P 500 Equal Weight ETF (RSP), a smart beta ETF with $95.93 billion in assets. RSP uses equal-weighting methodology rather than traditional market cap weighting, with a 0.20% expense ratio and 1.51% dividend yield. The fund has gained 11.2% year-to-date and 12.31% over the past year, with a beta of 0.92. The article compares RSP to alternative cap-weighted ETFs like IVV and VOO, which offer lower expense ratios (0.03%) and potentially lower risk for investors seeking traditional market exposure.

Merck's stock declined 7.2% recently after a strong 60% annual gain, but analysts view this as a healthy pullback. While the company faces near-term headwinds including Gardasil weakness, generic competition, and Keytruda's 2028 patent expiration, its expanding pipeline with 20 new drug launches expected by 2030 and strategic acquisitions position it for long-term growth. The company maintains a Hold rating with potential as a buying opportunity for long-term investors.

Novo Nordisk and Pfizer are compared as pharmaceutical giants navigating different challenges. Novo Nordisk boasts superior profitability with a 33% net margin and strong cash flow, but faces pricing pressures and competition in the GLP-1 weight-loss drug market. Pfizer trades at lower valuations and is improving net income through strategic acquisitions in oncology and obesity, though it faces significant patent cliffs through 2030. The article recommends Pfizer as the better buy in 2026 based on its value metrics and improving earnings trajectory.

Nasdaq announced that Moderna, Inc. (MRNA) will replace Warner Bros. Discovery, Inc. (WBD) as a component of the Nasdaq-100 Index effective October 9, 2026. The Nasdaq-100 Index tracks 100 of the largest Nasdaq-listed non-financial companies and is tracked by over 200 investment products with $800 billion in assets under management globally.

Moderna (MRNA) closed at $188.94, down 1.89% in the latest session, underperforming the S&P 500. Despite a strong monthly gain of 27.69%, the company faces headwinds with projected earnings of -$1.36 per share (down 166.67% YoY) and quarterly revenue expected at $888.78 million (down 12.52%). The stock holds a Zacks Rank #3 (Hold) rating with unchanged consensus estimates over the past 30 days.